
- Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology.
- JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year.
- The stock maintains a 100% “Buy” technical opinion from Barchart.
- Wall Street sentiment is bullish with multiple “Strong Buy” ratings and price targets up to $275.